Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option?

Autor: Einhorn LH; Lawrence H. Einhorn, MD; Nabil Adra, MD; and Nasser Hanna, MD, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; and Craig Nichols, MD, SWOG Chair's Office and Testicular Cancer Commons, Portland, OR., Adra N; Lawrence H. Einhorn, MD; Nabil Adra, MD; and Nasser Hanna, MD, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; and Craig Nichols, MD, SWOG Chair's Office and Testicular Cancer Commons, Portland, OR., Hanna N; Lawrence H. Einhorn, MD; Nabil Adra, MD; and Nasser Hanna, MD, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; and Craig Nichols, MD, SWOG Chair's Office and Testicular Cancer Commons, Portland, OR., Nichols C; Lawrence H. Einhorn, MD; Nabil Adra, MD; and Nasser Hanna, MD, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; and Craig Nichols, MD, SWOG Chair's Office and Testicular Cancer Commons, Portland, OR.
Jazyk: angličtina
Zdroj: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Sep 10; Vol. 38 (26), pp. 3073-3074. Date of Electronic Publication: 2020 Jul 07.
DOI: 10.1200/JCO.20.00702
Databáze: MEDLINE